In early 2015 Gebro Pharma breathed new air into the market by inaugurating a new therapeutic area: the respiratory area. The franchise opened its doors with a product that assisted patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Tovanor® Breezhaler® arrived and began to tackle a disease that affects more than 10% of the population, and therefore has an enormous socio-health impact.

According to the WHO, the number of COPD patients is expected to rise in the coming decades, mainly due to continued exposure to risk factors, as well as aging and population growth.
The drug Tovanor® Breezhaler®, glycopyrronium bromide, is a maintenance bronchodilator treatment which aims to relieve the symptoms of adult patients with COPD.

In 2022 we introduce Bemrist® Breezhaler® and Zimbus® Breezhaler®, two new treatment alternatives for patients with poorly controlled asthma. These drugs represent combinations of medical interest based on their clinical development program, their efficacy and safety results, the benefits provided compared to existing therapies, their components and their convenient dosage.